Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Evoncabtagene Pazurgedleucel · CTX110

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by CRISPR Therapeutics

Phase 1/2 Most advanced trial (none active)
CRSP Developer
1 Registered trials

What is Evoncabtagene Pazurgedleucel?

Evoncabtagene pazurgedleucel is a preparation of allogeneic T lymphocytes transduced with a chimeric antigen receptor directed against CD19 and gene-edited with CRISPR-Cas9 to remove the endogenous T-cell receptor. The CAR-T cells recognize and kill CD19-positive B-cell malignancies, and it is studied in B-cell lymphomas and B-cell acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CTX110
Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen), T-cell receptor (endogenous TCR, eliminated by gene editing) (binding partner it blocks)
Mechanism
Kills target cells, directed at CD19
Therapy area
Oncology
Developer
CRISPR Therapeutics AG (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04035434 Phase 1/2 B-cell Malignancy Terminated CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adult B Cell ALLB-cell LymphomaB-cell MalignancyNon-Hodgkin Lymphoma

Other drugs acting on CD19

More from CRISPR Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind Evoncabtagene Pazurgedleucel

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.